Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ISOLYTE E W/ DEXTROSE 5% IN PLASTIC CONTAINER vs PHEBURANE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Isolyte E with Dextrose 5% provides isotonic fluid, electrolytes (sodium, potassium, magnesium, chloride, acetate, gluconate), and calories (dextrose). Dextrose supplies glucose for cellular energy, electrolytes maintain acid-base balance and osmotic pressure, and acetate/gluconate serve as bicarbonate precursors to correct metabolic acidosis.
Pheburane (sodium phenylbutyrate) is a prodrug that is metabolized to phenylacetate, which conjugates with glutamine to form phenylacetylglutamine. This alternative pathway for nitrogen excretion reduces ammonia levels in patients with urea cycle disorders.
Fluid and electrolyte replacement in patients with normal or mildly depleted intravascular volume,Treatment and prevention of hypokalemia,Metabolic acidosis correction,Caloric supplementation when peripheral parenteral nutrition is indicated
Adjunct therapy for nitrogen removal in patients with urea cycle disorders (UCDs) involving deficiencies of carbamyl phosphate synthetase, ornithine transcarbamylase, or argininosuccinic acid synthetase,Off-label: Management of hyperammonemia in other conditions
Intravenous infusion; dose based on electrolyte deficits and maintenance requirements; typical adult maintenance: 50-100 m L/hour, up to 2-3 L/day.
Adults: 1 gram orally twice daily, increased as tolerated to 2 grams orally twice daily. Maximum dose: 20 grams per day.
Not applicable (dextrose and electrolytes are endogenous substances; distribution and elimination are rapid, with a functional half-life of minutes to hours depending on infusion rate and renal function).
Terminal elimination half-life is approximately 1-2 hours in patients with normal renal function. In patients with renal impairment, half-life may be prolonged (up to 4-6 hours), necessitating dose adjustment.
Dextrose is metabolized via glycolysis and the citric acid cycle. Acetate is metabolized primarily in the liver and muscle to bicarbonate. Gluconate is converted to glucose or metabolized via the pentose phosphate pathway.
Primarily hepatic and renal; hydrolyzed by esterases to phenylacetate; phenylacetate then conjugated with glutamine via acyl-Co A synthetase and acyl-Co A:glutamine N-acyltransferase to form phenylacetylglutamine.
Renal: 100% (as free water and electrolytes, not metabolized). Biliary/Fecal: negligible.
Primarily renal excretion. Approximately 50-80% of a dose is excreted unchanged in urine via glomerular filtration and tubular secretion. Biliary/fecal elimination is minimal (<5%).
Negligible (<5%) for dextrose and electrolytes; no specific binding proteins.
Approximately 10-20% bound to plasma proteins, primarily albumin. Binding is low and not clinically significant.
Dextrose: ~0.2 L/kg (total body water); Electrolytes: ~0.4 L/kg (extracellular fluid). Clinical meaning: distributes throughout total body water.
Volume of distribution is approximately 0.3-0.5 L/kg, indicating distribution primarily in extracellular fluid. Not extensively distributed into tissues.
Intravenous: 100%.
Oral bioavailability is approximately 80-100% after administration of the sodium phenylbutyrate prodrug. PHEBURANE itself is a prodrug; bioavailability refers to conversion to phenylacetate and then to phenylacetylglutamine.
Monitoring of electrolytes and volume status required; dosage adjustment not standardized; avoid in severe renal impairment (e GFR <30 m L/min/1.73 m²) due to risk of hyperkalemia and fluid overload.
Contraindicated in patients with GFR < 50 m L/min/1.73 m² due to risk of hyperammonemia.
No specific adjustment recommended; monitor electrolytes and acid-base balance; caution in severe hepatic impairment due to altered fluid clearance.
No specific adjustment recommended for Child-Pugh A or B. Use with caution in severe hepatic impairment (Child-Pugh C) due to limited data.
Weight-based: 100-150 m L/kg/day for maintenance; adjust for ongoing losses; use with caution in neonates and children with renal impairment.
Neonates and children: 4.5 to 5.9 grams/m²/day orally in 2 to 4 divided doses. Doses up to 12.5 grams/day have been used.
Consider reduced starting rates due to decreased renal function and increased risk of fluid overload; monitor electrolytes and volume status closely; adjust rate based on comorbidities.
No specific adjustments recommended; use with caution due to age-related renal decline. Monitor renal function and ammonia levels.
NOT FOR USE IN HYPERLACTATEMIA, SEVERE METABOLIC ALKALOSIS, OR SEVERE HEPATIC FAILURE; CONTAINS ALUMINUM WHICH MAY BE TOXIC WITH PROLONGED USE IN RENAL IMPAIRMENT; ADDITIVES MAY BE INCOMPATIBLE, CONSULT PHARMACIST.
None
Monitor serum electrolytes, fluid balance, and blood glucose. Use with caution in patients with heart failure, renal impairment, hepatic disease, or hyperglycemia. Hypersensitivity reactions may occur. Avoid rapid or large-volume infusion in patients with impaired glucose tolerance.
May cause fluid retention and electrolyte abnormalities (e.g., hypernatremia, hypokalemia) due to sodium content,Pancreatitis has been reported,Neurotoxicity with high plasma phenylacetate levels (e.g., somnolence, confusion, seizures),May impair platelet function; caution in bleeding disorders or surgery,Monitor ammonia levels, serum electrolytes, liver function, and complete blood counts regularly
Hypernatremia, hyperkalemia, hypermagnesemia, hypercalcemia, hyperlactatemia, severe metabolic alkalosis, severe hepatic failure, hyperglycemic states, anuria, or known hypersensitivity to any component.
Hypersensitivity to sodium phenylbutyrate or any component of the formulation,Patients in whom adequate nitrogen removal cannot be achieved or who are not suitable for alternative therapy (e.g., hemodialysis)
No known food interactions. However, patients with diabetes should be aware of dextrose content which affects blood glucose. Dietary potassium or magnesium restriction may be necessary if electrolyte imbalances occur.
Avoid high-protein foods as they increase ammonia production. Take with meals to improve tolerability. No known significant food-drug interactions.
No evidence of teratogenicity in animal studies or human data. Dextrose and electrolytes are essential nutrients; no structural anomalies attributed. However, hyperglycemia in uncontrolled maternal diabetes may cause fetal malformations. Use cautiously in gestational diabetes.
Pheburance (sodium phenylbutyrate) has not been studied in pregnant women. In animal studies, phenylbutyrate caused fetal harm at doses equivalent to human therapeutic doses. First trimester: Potential for teratogenicity based on animal data. Second and third trimesters: May cause fetal growth restriction and neurotoxicity due to ammonia-lowering effects. Use only if benefit outweighs risk.
Dextrose and electrolytes pass into breast milk but are normal milk constituents. No adverse effects expected in term infants. M/P ratio not determined as these are endogenous substances. Consider maternal fluid/electrolyte status.
It is unknown if sodium phenylbutyrate or its metabolites are excreted in human milk. The M/P ratio has not been established. Due to potential for serious adverse reactions in nursing infants, breastfeeding is not recommended during therapy.
No specific dose adjustment needed. Monitor for volume expansion in pregnancy (increased intravascular space). Adjust rate based on maternal glucose, electrolytes, and clinical response. Avoid excess dextrose in gestational diabetes.
Pregnancy may alter pharmacokinetics of sodium phenylbutyrate due to increased plasma volume, renal clearance, and hepatic metabolism. Although specific dose adjustment recommendations are lacking, consider monitoring ammonia levels closely and titrating dose to maintain therapeutic ammonia control. Dose may need to be increased in late pregnancy and postpartum. Start at the lowest effective dose.
ISOLYTE E W/ DEXTROSE 5% is an isotonic, balanced electrolyte solution with 5% dextrose for parenteral replacement of fluid and electrolytes. It contains potassium, magnesium, and acetate (bicarbonate precursor). Avoid in patients with hyperkalemia, hypermagnesemia, or metabolic alkalosis. Monitor serum electrolytes, glucose, and renal function. Use with caution in heart failure, renal impairment, and patients at risk for fluid overload. Do not administer if cloudy or precipitate present. Discard any unused portion.
PHEBURANE (sodium phenylbutyrate) is used as adjunctive therapy for urea cycle disorders. Monitor plasma ammonia, arginine, and glutamine levels. Avoid in patients with severe hepatic impairment. Discontinue if hyperammonemic encephalopathy occurs.
This solution provides fluids, sugar, and electrolytes to correct imbalances.,Your healthcare team will monitor your blood sugar and electrolyte levels during treatment.,Report any symptoms like swelling, shortness of breath, or changes in urination.,This medication is given only in a hospital or clinic setting by a healthcare professional.,Tell your doctor if you have any allergies, especially to corn (dextrose source).
Take with food or milk to reduce gastrointestinal irritation.,Do not crush or chew tablets; swallow whole.,Report any signs of hyperammonemia (e.g., lethargy, vomiting, confusion) immediately.,Maintain a low-protein diet as prescribed.,Store at room temperature away from moisture and heat.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ISOLYTE E W/ DEXTROSE 5% IN PLASTIC CONTAINER vs PHEBURANE, answered by our medical review team.
ISOLYTE E W/ DEXTROSE 5% IN PLASTIC CONTAINER is a Intravenous Electrolyte Solution with Dextrose that works by Isolyte E with Dextrose 5% provides isotonic fluid, electrolytes (sodium, potassium, magnesium, chloride, acetate, gluconate), and calories (dextrose). Dextrose supplies glucose for cellular energy, electrolytes maintain acid-base balance and osmotic pressure, and acetate/gluconate serve as bicarbonate precursors to correct metabolic acidosis.. PHEBURANE is a Ammonia Detoxicant that works by Pheburane (sodium phenylbutyrate) is a prodrug that is metabolized to phenylacetate, which conjugates with glutamine to form phenylacetylglutamine. This alternative pathway for nitrogen excretion reduces ammonia levels in patients with urea cycle disorders.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ISOLYTE E W/ DEXTROSE 5% IN PLASTIC CONTAINER and PHEBURANE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ISOLYTE E W/ DEXTROSE 5% IN PLASTIC CONTAINER is: Intravenous infusion; dose based on electrolyte deficits and maintenance requirements; typical adult maintenance: 50-100 m L/hour, up to 2-3 L/day.. The standard adult dose of PHEBURANE is: Adults: 1 gram orally twice daily, increased as tolerated to 2 grams orally twice daily. Maximum dose: 20 grams per day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ISOLYTE E W/ DEXTROSE 5% IN PLASTIC CONTAINER and PHEBURANE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ISOLYTE E W/ DEXTROSE 5% IN PLASTIC CONTAINER is classified as Category C. No evidence of teratogenicity in animal studies or human data. Dextrose and electrolytes are essential nutrients; no structural anomalies attributed. However, hyperglycemia in unco. PHEBURANE is classified as Category C. Pheburance (sodium phenylbutyrate) has not been studied in pregnant women. In animal studies, phenylbutyrate caused fetal harm at doses equivalent to human therapeutic doses. First. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.